Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 28 02:59PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.66 Insider Own56.29% Shs Outstand63.70M Perf Week10.12%
Market Cap212.27M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float29.15M Perf Month17.43%
Income-41.16M PEG- EPS next Q- Inst Own2.23% Short Float / Ratio2.19% / 2.97 Perf Quarter22.40%
Sales0.00M P/S- EPS this Y- Inst Trans-3.67% Short Interest0.64M Perf Half Y237.12%
Book/sh0.71 P/B4.47 EPS next Y- ROA-58.53% Target Price- Perf Year80.82%
Cash/sh0.01 P/C408.20 EPS next 5Y- ROE-70.32% 52W Range0.39 - 5.25 Perf YTD208.97%
Dividend- P/FCF- EPS past 5Y-19.64% ROI-86.71% 52W High-39.38% Beta0.32
Dividend %- Quick Ratio0.19 Sales past 5Y0.00% Gross Margin- 52W Low710.18% ATR0.38
Employees12 Current Ratio0.19 Sales Q/Q- Oper. Margin0.00% RSI (14)51.15 Volatility12.79% 11.60%
OptionableYes Debt/Eq0.10 EPS Q/Q-1.86% Profit Margin- Rel Volume0.31 Prev Close3.43
ShortableYes LT Debt/Eq0.02 Earnings- Payout- Avg Volume215.01K Price3.18
Recom- SMA207.12% SMA50-9.45% SMA20079.62% Volume56,987 Change-7.22%
Nov-23-23 09:30AM
Nov-22-23 10:44AM
Nov-21-23 08:30AM
Nov-14-23 09:00AM
Nov-10-23 08:30AM
08:30AM Loading…
Nov-07-23 08:30AM
Oct-24-23 09:00AM
Oct-11-23 09:25AM
Oct-10-23 08:00AM
Oct-04-23 09:00AM
Oct-02-23 12:05PM
Sep-29-23 09:15AM
09:15AM Loading…
Sep-21-23 03:00PM
Sep-19-23 08:30AM
Sep-06-23 12:40AM
Aug-30-23 09:15AM
Aug-21-23 09:15AM
Aug-10-23 12:06AM
Aug-09-23 09:00AM
Jul-17-23 07:29AM
Jun-23-23 05:00PM
Jun-08-23 08:45AM
Apr-03-23 09:00AM
Mar-29-23 09:00AM
Mar-13-23 08:30AM
Feb-23-23 04:04PM
05:20PM Loading…
Nov-30-22 05:20PM
Oct-26-22 12:01AM
Oct-24-22 08:11PM
Oct-21-22 05:00PM
Oct-17-22 08:30AM
Sep-01-22 08:08AM
Jul-25-22 10:15AM
Jul-01-22 08:37PM
Jun-27-22 03:00PM
Jun-10-22 04:00PM
Jun-09-22 05:59PM
May-31-22 08:00AM
May-25-22 04:20PM
Apr-20-22 07:00AM
Apr-07-22 06:00AM
Apr-06-22 09:07AM
Apr-05-22 06:00AM
Mar-25-22 12:07PM
Mar-15-22 07:00AM
Dec-03-21 07:00AM
Oct-18-21 07:00AM
Oct-15-21 06:00PM
Oct-12-21 06:00PM
Sep-27-21 07:00AM
Sep-26-21 10:42AM
Sep-13-21 07:00AM
Aug-30-21 07:00AM
Aug-23-21 10:18AM
Jul-20-21 07:00AM
Jul-12-21 08:37AM
Jun-30-21 07:00AM
Jun-21-21 05:31PM
Jun-15-21 09:05AM
Jun-14-21 03:15PM
May-12-21 04:29PM
Apr-30-21 03:42AM
Mar-24-21 06:00PM
Feb-22-21 05:15PM
Nov-01-20 09:35AM
Sep-10-20 12:50AM
Jul-27-20 08:00AM
Jun-08-20 07:30AM
May-14-20 09:50AM
May-13-20 08:00AM
Apr-23-20 07:00AM
Apr-09-20 10:00AM
Feb-24-20 07:30AM
Feb-03-20 07:30AM
Jan-06-20 07:30AM
Dec-10-19 07:00AM
Nov-25-19 07:00AM
Nov-21-19 10:30AM
Oct-31-19 04:17PM
Oct-26-19 10:18AM
Jun-03-19 07:00AM
Apr-29-19 09:19AM
Mar-07-19 12:45PM
Feb-01-19 02:31PM
Jan-16-19 04:00PM
Jan-07-19 08:30AM
Renovaro Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.